4//SEC Filing
Hirsch Stanley 4
Accession 0001209191-20-018227
CIK 0001566044other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 5:57 PM ET
Size
16.0 KB
Accession
0001209191-20-018227
Insider Transaction Report
Form 4
Hirsch Stanley
Director
Transactions
- Award
Common Stock
2020-03-09+31,303→ 31,303 total - Award
Common Stock
2020-03-09+108,113→ 108,113 total(indirect: See footnote) - Award
Stock Options
2020-03-09+29,481→ 29,481 totalExercise: $8.48From: 2020-03-09Exp: 2028-05-08→ Common Stock (29,481 underlying) - Award
Common Stock
2020-03-09+34,960→ 66,263 total - Award
Stock Options
2020-03-09+15,994→ 15,994 totalExercise: $9.93From: 2020-03-09Exp: 2024-12-29→ Common Stock (15,994 underlying) - Award
Stock Options
2020-03-09+48,667→ 48,667 totalExercise: $7.92Exp: 2027-07-13→ Common Stock (48,667 underlying)
Footnotes (4)
- [F1]Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020.
- [F2]Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch.
- [F3]Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.
- [F4]The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
Documents
Issuer
Menlo Therapeutics Inc.
CIK 0001566044
Entity typeother
Related Parties
1- filerCIK 0001727864
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 5:57 PM ET
- Size
- 16.0 KB